Epinephrine

證據等級: L5

預測適應症: 4 個

Epinephrine: From Anaphylaxis to Obstructive Lung Disease

One-Sentence Summary

Epinephrine (adrenaline) is classically used as an emergency treatment for anaphylaxis, cardiac arrest, and acute bronchospasm. The TxGNN model predicts it may also be broadly effective for Obstructive Lung Disease, a prediction already substantially supported by 50 clinical trials and 20 publications — several of which directly test inhaled or nebulized epinephrine in asthma and bronchiolitis. However, epinephrine currently holds no marketing authorization in Finland, and a Blocking-severity data gap in TFDA/Fimea package-insert warnings means the candidate cannot yet enter formal (S1) safety screening.

Quick Overview

Item	Content
Original Indication	Not on file in Finland regulatory data (0 licenses, unmarketed); epinephrine's well-established classic uses are anaphylaxis, cardiac arrest, and acute bronchospasm/asthma
Predicted New Indication	Obstructive Lung Disease
TxGNN Prediction Score	99.71%
Evidence Level	L1
Finland Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails (conditional on resolving safety data gap)

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not currently available from DrugBank for this candidate (flagged as data gap DG002, High severity). Based on well-established pharmacology, however, epinephrine is a nonselective α/β-adrenergic receptor agonist. Its β2-receptor activity produces bronchial smooth-muscle relaxation (bronchodilation), while its α1-receptor activity reduces airway mucosal vascular congestion and edema — both actions directly counteract the airflow limitation that defines obstructive lung disease.

Critically, this is not a purely theoretical extrapolation: epinephrine already has a documented history of use in acute bronchospasm and asthma. The historical over-the-counter inhaler Primatene Mist, its investigational HFA reformulation (E004), and nebulized "racemic epinephrine"/adrenaline are all epinephrine-based products that have been directly studied in asthma and infant bronchiolitis — both recognized subtypes of obstructive lung disease. This is reflected in the trial evidence below, where multiple studies test epinephrine formulations head-to-head against albuterol, hypertonic saline, and placebo in exactly this disease space.

Because the mechanistic pathway is pharmacologically well characterized and the "new" indication substantially overlaps with epinephrine's existing off-label/legacy respiratory use, this candidate reaches a relatively mature decision stage (S3) with an L1 evidence level, despite the drug lacking a current Finland indication record.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01357642	Phase 3	Completed	373	12-week efficacy/safety of Epinephrine HFA Inhalation Aerosol MDI vs. placebo-HFA and marketed Primatene® Mist (CFC epinephrine inhaler) in adolescents/adults with asthma.
NCT01300325	Phase 4	Completed	136	Nebulized 3% hypertonic saline vs. normal saline, both with epinephrine, in RSV-positive hospitalized infants with bronchiolitis.
NCT02586961	Phase 2/3	Terminated	195	Combined nebulized adrenaline + oral betamethasone tested as an alternative to reduce hospitalization for acute bronchiolitis in pediatric emergency departments.
NCT05363670	Phase 2	Completed	18	Cross-over safety/efficacy study of intranasal epinephrine (ARS-1) vs. albuterol as a needleless route for refractory asthma symptom management.
NCT04207840	Phase 4	Completed	28	Crossover PK comparison of inhaled Primatene Mist (epinephrine) vs. IM epinephrine injection vs. inhaled ProAir (albuterol) in healthy adults.
NCT03614273	NA	Completed	60	RCT comparing nebulized 3% hypertonic saline vs. nebulized adrenaline for bronchiolitis, including response in initial non-responders.
NCT01255709	Phase 2	Completed	24	Deuterium-labeled PK study of epinephrine HFA-MDI (E004) inhalation aerosol distinguishing exogenous from endogenous epinephrine.
NCT00114478	NA	Unknown	600	RCT comparing epinephrine and albuterol, the two most commonly used bronchodilators, in bronchiolitis.
NCT01737892	Phase 1/2	Terminated	21	Follow-up PK/safety study of epinephrine HFA-MDI (E004) using deuterium-labeled epinephrine in healthy volunteers.
NCT01216553	Phase 4	Unknown	135	Home oxygen therapy vs. standard nebulized therapy (0.1% epinephrine + bromhexine or hypertonic saline) in ambulatory infant bronchiolitis.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
21678340	2011	Cochrane Review	The Cochrane Database of Systematic Reviews	"Epinephrine for bronchiolitis" — systematic review of bronchodilator use; effectiveness remains uncertain despite common practice.
14974006	2004	Cochrane Review	The Cochrane Database of Systematic Reviews	Earlier Cochrane review version; bronchodilators show modest short-term benefit in mild-to-moderate bronchiolitis.
30488718	2019	Review	Expert Review of Respiratory Medicine	Reviews the role of racemic epinephrine, corticosteroids, hypertonic saline, and high-flow oxygen in pediatric bronchiolitis therapy.
6777857	1980	Cohort	Scandinavian Journal of Clinical and Laboratory Investigation	Elevated plasma noradrenaline in chronic obstructive lung disease patients, correlated with hemodynamics and blood-gas abnormalities.
21486501	2011	Review	BMJ Clinical Evidence	Overview of bronchiolitis epidemiology and treatment as the most common infant lower respiratory tract infection.
19450362	2007	Review	BMJ Clinical Evidence	Earlier edition of the same bronchiolitis clinical-evidence review.
4606289	1974	Pending classification	Clinical Pharmacology and Therapeutics	"Bronchodilator effects of terbutaline and epinephrine in obstructive lung disease" — direct historical comparison of epinephrine's bronchodilator effect.
4551435	1972	Pending classification	Annals of Allergy	"Nebulized bronchodilators in obstructive lung disease II" — early evaluation of nebulized bronchodilator therapy including epinephrine.
6417212	1983	Review	Journal of Allergy and Clinical Immunology	Review of childhood asthma pathophysiology, characterizing asthma as an obstructive airway disease.
30856157	2019	Other	The Medical Letter on Drugs and Therapeutics	Coverage of the OTC return of Primatene Mist (epinephrine inhaler) for asthma symptom relief.

Finland Market Information

Epinephrine currently holds no marketing authorization on file in Finland (0 licenses; market status: 未上市 / Not Marketed). No product name, dosage form, or approved-indication text is available from the regulatory data source for this candidate.

Safety Considerations

No structured safety data (key warnings, contraindications, or drug-drug interactions) is currently available for this candidate — the DDI query returned not_found with zero interactions on record. Please refer to the package insert for safety information.

Note on safety data status: This is flagged in the evidence pack as a Blocking-severity gap (DG001) — the absence of TFDA/Fimea package-insert warnings and contraindications means this candidate cannot yet proceed to the S1 safety initial evaluation stage, independent of how strong the efficacy/mechanistic evidence is for the predicted indication. Remediation requires downloading and parsing the official package insert PDF from the relevant regulatory source.

Other TxGNN-Predicted Indications (Not Prioritized)

The evidence pack scored three additional candidate indications for epinephrine, none of which are recommended to advance at this time:

Rank	Indication	Score	Evidence Level	Recommendation	Note
2	Food-Dependent Exercise-Induced Anaphylaxis (FDEIA)	99.57%	L3	Proceed with Guardrails	Strong mechanistic rationale (epinephrine is standard anaphylaxis rescue therapy) but no clinical trials — 20 review/case-level publications only; represents an indication-label extension rather than new pharmacology.
3	Rienhoff Syndrome	99.57%	L5	Hold	No clinical trials, no literature, no mechanistic link to adrenergic pharmacology (a rare LTBP3-related connective tissue disorder). Likely model noise/false positive from sparse rare-disease training data — not a meaningful signal.
4	Respiratory Malformation	99.56%	L4	Hold	Evidence retrieved is mismatched to the disease label — trials and literature relate to functional respiratory emergencies (cardiac arrest resuscitation, croup/upper-airway obstruction) rather than structural airway malformation. Requires disease-label clarification before further evaluation.

Conclusion and Next Steps

Decision: Proceed with Guardrails (Conditional on Safety Data)

Rationale: The top-ranked prediction — epinephrine for obstructive lung disease — is supported by an L1 evidence level, including a completed Phase 3 RCT (NCT01357642, N=373) and a substantial, epinephrine-specific trial record spanning both asthma and bronchiolitis. This is less a novel prediction than a data-driven reconfirmation of epinephrine's existing legacy respiratory use. However, the candidate cannot move past initial safety screening until the Blocking-severity package-insert data gap (DG001) is resolved, and Finland market status (unmarketed, 0 licenses) still needs a defined regulatory pathway.

To proceed, the following is needed:

TFDA/Fimea package insert (warnings and contraindications) — Blocking gap (DG001), required before S1 safety evaluation
Confirmed DrugBank mechanism-of-action record — High-priority gap (DG002), to support mechanistic-link analysis
A defined Finland regulatory/registration pathway, given the drug is currently unmarketed with zero licenses
A completed drug-drug interaction (DDI) query, since the current query returned no results
Route-compatibility confirmation (available vs. required administration routes), currently marked "pending" in the evidence pack
Disease-label verification for "respiratory malformation" (rank 4), where retrieved evidence does not match the stated indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.